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Abstract: 38 
The current study investigates the dissolution rate performance of amorphous solid solutions 39 
of poorly water soluble drug, efavirenz (EFV) in amorphous Soluplus® (SOL) and Kollidon® 40 
VA64 (KVA64) polymeric systems. For the purpose of the study various formulations with 41 
varying drug loadings of 30% 50% and 70 % w/w were developed via hot-melt extrusion 42 
processing and adopting a Box-Behnken design of experiment (DoE) approach. The polymers 43 
were selected based on the Hansen solubility parameters calculation and the prediction of the 44 
possible drug-polymer miscibility. In DoE experiments, Box Behnken factorial design was 45 
conducted to evaluate effect of independent variables such as , Soluplus® ratio (A1), HME 46 
screw speed (A2), and processing temperature (A3); Kollidon®VA64 ratio (B1), screw speed 47 
(B2),and processing temperature (B3) on responses such as solubility (X1 and Y1), dissolution 48 
rate (X2 and Y2) for both ASS [EFV:SOL] and BSS [EFV:KVA64] systems. DSC and XRD 49 
data confirmed that bulk crystalline EFV transformed to amorphous form during the HME 50 
processing. Advanced chemical analyses conducted via 2D COSY NMR, FTIR chemical 51 
imaging, AFM analysis and FTIR   showed that EFV was homogenously dispersed in the 52 
respective polymer matrices. The maximum solubility and dissolution rate was observed in 53 
formulations containing 30% EFV with both SOL and KVA64 alone. This could be attributed 54 
to the maximum drug-polymer miscibility in the optimized formulations. The actual and 55 
predicted values of both responses were found precise and close to each other.  56 
 57 
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1. Introduction  74 
Efavirenz (EFV) is used as a first line therapeutic drug  for HIV-I and is a specific non-75 
nucleoside reverse transcriptase inhibitor. EFV is a white crystalline powder, belongs to class 76 
II of biopharmaceutical classification system (BCS) and exhibit very poor solubility and 77 
dissolution rate which results into very low and variable oral bioavailability [1-3]. Whilst, EFV 78 
is the most promising chemical entity against HIV-I therapy, the limited solubility and thus 79 
bio-availability makes the successful delivery of this drug very challenging. Therefore, there is 80 
an immense  need for the implementation of a suitable formulation strategy to overcome the 81 
issues associated with poor water solubility of  EFV.  82 
Hot-melt extrusion (HME) has become a well-known processing technology in the 83 
development and manufacturing of amorphous solid dispersion or solid solution systems. In 84 
such systems a crystalline drug is covered into amorphous form or a molecularly dispersed 85 
system is formed [4]. In recent years combinatorial chemistry and high throughput screening 86 
has resulted into rise in the number of poorly water soluble drugs found in pharmaceutical 87 
discovery pipeline [5]. Sufficient aqueous solubility and bioavailability is needed for optimum 88 
oral absorption of a drug candidate. As a result, scientists from industry as well as academia 89 
are working together on several aspects of solubility enhancements of challenging drug 90 
candidates to tackle the growing and unmet need.  91 
Amorphous solid solutions or solid dispersions are known as highly supersaturated 92 
category of drug delivery systems. These systems have attracted a lot of research interests, due 93 
to the ability of these systems  to facilitate an improved solubility and oral bioavailability of 94 
poorly water-soluble crystalline drugs [6, 7]. The glassy molecular dispersion of drug in an 95 
amorphous polymer matrix is termed as solid solutions (SS). In order to form a miscible and 96 
thermodynamically stable molecular system, one has to consider complete miscibility of the 97 
drug in a suitable polymeric system below its saturation solubility, and therefore drug-polymer 98 
miscibility is of great importance for the development of the concept of  SS [8, 9]. In the present 99 
context, instead of traditional methods for the preparation of SS such as solvent evaporation, 100 
and spray drying techniques, we have used HME as the most promising solvent-free, 101 
continuous and industry feasible and scalable process for the preparation of EFV SS [10].  We 102 
are reporting preparation of EFV solid solutions by HME technology  using two widely used 103 
thermostable amorphous polymers; Soluplus® (SOL) (polyvinyl caprolactam polyvinyl acetate 104 
polyethylene glycol graft copolymer) and Kollidon® VA64 (KVA64) (Vinylpyrrolidone-vinyl 105 
acetate copolymer) by adopting a Quality by Design (QbD) approach. Both polymers are 106 
amphiphilic in nature that can work as solubilizing agent and have been reported in the 107 
literature for dissolution enhancement of other poorly water soluble drugs[11-13].  108 
Response surface methodology (RSM), is one of the techniques used to study possible 109 
effects, their interactions on shape of response surface and quadratic effects for formulation 110 
optimization. The Box-Behnken Design (BBD) is a method to understand effect of formulation 111 
variables (independent factors) on their effect on formulation responses (dependent variables) 112 
as shown in fishbone diagram (Fig.1).  BBD is considered to be more efficient and most 113 
powerful than other designs such as central composite design, three level full factorial design 114 
due to the fact that it requires fewer experimental runs compared to other techniques, hence it 115 
is less expensive [14]. The experimental treatment combinations are placed at midpoints of 116 
edges and at center of process space, giving higher percentage yields as well as less treatment 117 
time with minimum costs [15]. Drug-polymers miscibility has been investigated by the Hansen 118 
solubility parameter (HSP). The HSP calculation is a tool for the theoretical predication of 119 
drug-polymer miscibility at preformulation stage prior to the HME processing [16].  In this 120 
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study, we have demonstrated BBD as a part of RSM technique to study the effects of processing 121 
parameters for the formulation of solid solutions (SS) of Efavirenz (EFV) using HME.  122 
2. Material and methods: 123 
2.1 Materials 124 
Efavirenz (EFV) was a kind gift from Laurus Labs, India. Both Soluplus and Kollidon 125 
VA64 were kindly donated by BASF Corporation, Mumbai, India. Marketed sample of EFV 126 
tablets AVIRANZ® (100 mg) was purchased from retailers shop in Mumbai, India. All other 127 
chemicals and solvents used were of analytical grade and were procured from SD fine 128 
Chemicals, Mumbai, India. Milli-Q water was used throughout the study. 129 
2.2 Box Behnken Factorial design: 130 
Box-Behnken design with 3 factors, 3 levels was employed to develop EFV SS systems. 131 
The HME experimental design and data analysis was conducted using licensed version of 132 
Design expert® software (version 9.0.4.1; M/s, Stat-Ease, Minneapolis, USA). The adopted 133 
Box-Behnken design resulted in 13 runs each for both polymers and wereused for optimization 134 
study (Fig.1 is in supplementary information). Three factors such as different polymer ratios, 135 
variable screw speed and variable temperature of the process were used as independent 136 
variables for preparation of SS. A full quadratic model was ﬁtted to collect responses, and P 137 
values and were used to determine their effect on HME process [19]. The effect of independent 138 
variables [SOL ratio (A1), variable screw speed (A2) and variable temperature (A3)] as well as 139 
[KVA64 ratio (B1), variable screw speed (B2) and variable temperature (B3)] on dependent 140 
variable [Solubility (X1 & Y1) and dissolution rate enhancement (X2 & Y2)], where (X refers to 141 
SOL and Y refers to KVA64) in EFV SS were studied as shown in Table 1.  142 
The linear equation of the model is as follows: 143 
 144 
Y= b0 + b1A1 + b2A2 + b3A3 + b12A1A2 + ……..bnXn             Eq. [I] 145 
 146 
Where Y is the response, b0 is the constant and b1 b2 …… bn is the coefficient of factor A1, A2… 147 
An …as well as …... B1, B2… Bn. is representing the effect of each ordered within -1, +1. 148 
The DoE software designed 13 experimental runs for each polymer respectively as 149 
mentioned in Table 2. One-way ANOVA and multilinear regression analysis were performed 150 
to test the significance of Box- Behnken model and factor coefficients. As per ICH guideline, 151 
Q8 outlines different terms and steps involved in EFV SS tablet manufacturing process, all 152 
steps involved in this study are shown in (Fig.1 in supplementary information). 153 
 154 
2.3 HME process to manufacture solid solutions (SS) of EFV 155 
EFV SS formulations were prepared using  single-screw Lab Hot Melt Extruder (S.B. 156 
Panchal and Co., India) equipped with stainless  steel  single  screw  with  diameter  of  24.5mm  157 
and  length  of  5.8  inch. The  barrels  have  feeder,  conveyer,  mixing  sections,  and  carrier  158 
zone  with  internal  diameter 25.5mm  and  length  of  6  inch  attached  with  a  round  shaped  159 
die  (2  mm  in  diameter). The processing temperatures were selected based on Tg of polymers 160 
and melting point of EFV in order to obtain transparent extrudates which were further termed 161 
as solid solutions (SS). The obtained extrudes of EFV SS were stored in a desiccator at room 162 
temperature for further physicochemical characterization. The drug loading was kept constant 163 
30% as shown in and independent variables i.e. polymer ratios were varied as shown in Table 164 
2. All 26 batches were processed as recommended by DoE runs. The different weight ratios of 165 
polymer to drug, different temperature processing ranges from 110°C - 140°C were applied to 166 
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obtain semi-solid, transparent extrudates for each formulation suitable for downstream 167 
processing of EFV SS to formulate tablet dosage form. 168 
 The optimized batches ASS10 and BSS9 specified by DoE were further processed on 169 
a production scale pilot Twin-screw HME instrument (ACG Pharma Machinery Pvt. Ltd. India) 170 
with batch size of 500gm each. The obtained extrudates were further milled using Multimill 171 
(ACG Pharma Tech, India). The milled granules stored in airtight containers until further 172 
physicochemical characterization.  173 
 174 
2.3.1 Downstream processing of EFV SS granules to form tablets: 175 
 The prepared granules each from optimized batch i.e. ASS10 and BSS9 of EFV SS of 176 
500gm each were further compressed using a Rimek Tablet compression machine to form 177 
tablets with dose equivalent to 100mg of EFV.  178 
2.4 Physicochemical characterization of EFV ASDs 179 
2.4.1 Saturation solubility study 180 
Saturation solubility study was carried out for neat EFV and SS of EFV in 2% sodium 181 
lauryl sulfate (SLS) distilled water maintained at 37 ± 0.5 °C by adding excess quantities of 182 
API and SS were added to 10 ml of dissolution media and capped glass test tubes were kept in 183 
a shaking hot tub (Boekel scientific, USA) at 37±0.5°C, 30 rpm for 72 hrs. The supernatant 184 
solution was then filtered through 0.45µm millipore membrane filter and suitably diluted and 185 
analyzed for drug content in triplicate using UV-visible spectroscopy. 186 
2.4.2 In vitro dissolution studies 187 
The dissolution studies were conducted using a USP type II dissolution apparatus. The 188 
EFV SS tablets equivalent to 100 mg of API were placed in dissolution medium within 189 
apparatus for 60 min along with pure EFV and marketed tablet formulation (100mg dose). The 190 
dissolution medium was 2% sodium lauryl sulfate (SLS) in distilled water; 900 mL maintained 191 
at 37 ± 0.5 °C (pH of about 4.5 to 5.5) and the paddle rotation speed was 50 rpm. SS tablets 192 
equivalent to 100 mg of EFV were taken along with pure EFV drug (100 mg) subjected to same 193 
dissolution study [3]. At various time points like 5, 15, 30, 45 and 60min, the 10 ml of 194 
respective samples were withdrawn and an equal amount of fresh preheated medium 37 ± 0.5 195 
°C was added to ongoing dissolution medium vessel. These samples were analysed using UV-196 
spectrophotometer at 248 nm. The dissolution studies were performed in triplicate.  197 
 198 
2.4.3 Differential Scanning Calorimetry (DSC) 199 
DSC analysis was performed to check the solid state of the drug in the manufactured 200 
SSwith respect to pure EFV, SOL and KVA64 and optimized batches of ASS10 and BSS9 201 
using Pyris-6 DSC Perkin Elmer (USA).  The samples equivalent to 3-4 mg of was hermetically 202 
sealed in aluminum pan. The samples were then heated  from  30°C - 300°C at  rate  of  203 
10°C/min-1 under an inert atmosphere using purging nitrogen gas at a flow rate of 17-18 204 
ml/min. An empty aluminum pan was used as a blank. The Pyris® manager software was used 205 
for post experimental analysis.   206 
 207 
2.4.4 X-ray powder diffraction (PXRD) analysis 208 
PXRD was used to determine the solid state of EFV SS made from extrudates along 209 
with other bulk materials using a Bruker D8 Advance in theta–theta mode. For PXRD study of 210 
SS, a Cu anode at 40 kV and 20 mA current was set, Soller slits (0.04 rad) were used in incident 211 
and diffracted beam path at sample rotation set at 15 rpm. Each sample was scanned from 2 to 212 
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50° 2 θ with a step size of 0.02° 2θ and a counting time of 0.3 seconds per step. The samples 213 
were placed in a zero background sample holder and incorporated on a spinner stage.  214 
2.4.5 Structural analysis by FTIR 215 
FTIR analysis was undertaken to investigate the molecular structures of EFV, SOL, 216 
KVA64, ASS10, and BSS9. The samples were analyzed for  their  functional  group 217 
identification  using  Shimadzu  MIRACLE  IR  Affinity-1  FTIR spectrophotometer.  The  218 
samples  were  premixed  with  KBr  using  mortar  and  pestle  and KBr disks were prepared 219 
by means of a hydraulic press. The scanning range was 4000 to 400 cm-1 with resolution of 4 220 
cm-1. 221 
2.4.6 FTIR Spectroscopic Imaging 222 
Fourier transform infrared imaging was conducted on a continuous scan spectrometer 223 
coupled with a macro sample chamber (Hyperion 3000, Bruker Optics GmbH, Ettligen, 224 
Germany) and a Focal Plane Array (FPA) detector 128 × 128, (Santa Barbara Focal plane, 225 
Goleta, California) at range: 4000-900 cm−1.  The thin film of extrudate obtained by cutting a 226 
rod of extrudates using a sharp razor of ASS10 was placed on crystal accessory; position of 227 
accessory was adjusted so that a good focused image could be obtained. The images were 228 
acquired with a spectral resolution of FTIR 8cm−1, and 32 co-added scans with the help of 229 
OPUS® 6.5 software with an acquisition time of approximately 2min.  230 
2.4.7 Atomic force microscopy (AFM) characterization 231 
Sample for AFM was prepared by cutting the freshly prepared extrudates with smooth 232 
surfaces (Cross section of extrudates) by a razor blade. All extrudates with cylindrical rods of 233 
20 mm and 50 mm were selected, and placed on a glass slide. The sample was placed such that 234 
it should keep its position horizontally, as this is required to get non-destructive imaging by 235 
atomic force microscope operations [20, 21]. AFM analysis was carried out using AFM 236 
instrument of DFRT-PFM on a commercial SPM system (Asylum Research MFP-3D, 237 
California, USA) with a nitrogen flow cell positioned above an inverted optical microscope. 238 
AFM with accelerating voltage up to ± 220 V and imaging at AC voltages up to 110 Vpp (in 239 
the dual-excitation mode) at frequencies of 300–400 kHz. Voltages were applied between the 240 
ITO substrate and the conductive probe tips, and AFM’s preamplifier (Asylum Research 241 
ORCA head model59) recorded current. The light source used in the AFM instrument is 242 
superluminescent diode (SLD), classified as Class 1M light source [22]. This enables 243 
polarization switching in extrudes samples and imaging of samples with maximum resolution 244 
and magnification. An AFM scans the surface of a specimen with a sharp tip mounted to a 245 
cantilever (Olympus TR400PB cantilevers), the deflections are directly related to surface micro 246 
scale topography and its physical properties [20, 23]. Height, phase and amplitude images were 247 
collected simultaneously; using Platinum-coated, contact-mode AFM tips were used. The 248 
result data was processed using Open user interface based on IGOR Pro software with 249 
OpenGL® 3D for advanced image display.  250 
 251 
 252 
2.4.8 1H COSY or 2D NMR analysis 253 
The 2D COSY NMR   experiments   were   carried   out   on   prepared   SS i.e. ASS10 254 
and BSS9 using   a   Varian   Mercury   Plus   300   NMR spectrometer   operated   at   300   255 
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MHz   with   cross   polarization   contact time   of   1  ms,   pulse   repeat   time   of   1 s,   256 
accumulation   of   1000   scans, and   high-power   1H-decoupling   of   100   kHz   during   257 
signal   acquisition   with   a  - 80º   to   130 º  with   suitable   solvent.   Sufﬁcient   SS   powder 258 
sample   was   dissolved   in   solvent   DMSO   and   then   used   for   analysis [23, 24]. Sample   259 
was   spun   at   a   rate   of 5 kHz   at   magic   angle   with   2D   width   4807.7 Hz.   5 mm   260 
multi   nuclear CP-MAS   probe   for   solids   application   was   used.   Data   processing   was 261 
carried   out   using   sine   bell   software   with   FT   size   2048 × 2048   and for   total   time   262 
of   65   min. 263 
 264 
2.4.9 Analytical method (HPLC) 265 
The assay of the ASDs was assessed using high-performance liquid chromatography 266 
(HPLC) system of JASCO corporation equipped with auto sampler (AS-2055 plus, intelligent 267 
sampler), photodiode array detector (JASCO corp.). A Phenomenex Luna® reverse-phase C18 268 
column (150 x 4.6 mm; 5µm particles) was used as a stationary phase. The mobile phase was 269 
composed of a mixture of buffer (Ammonium acetate buffer, pH maintained at 7.5): acetonitrile 270 
in the ratio 40:60 (v/v). The buffer was prepared by dissolving ammonium acetate in 1000 mL 271 
of water; maintain the pH at 7.5 ± 0.05. The flow rate was 1.5 mL/min, with injection, volume 272 
was 20 µL and the detection of EFV was done at 248 nm with the retention time of 3.38 ± 273 
0.05min. Drug content uniformity was assessed by accurately weighing ASDs equivalent to 10 274 
mg of EFV were dissolved in 10 mL of methanol and appropriately diluted. These samples 275 
further centrifuged (Centrifuge Eppendorf) for 5 min at 5000 rpm and drug content was 276 
quantified using previously delineated HPLC procedure.  277 
3. Result and discussions 278 
3.1 Design of Experiments (DoE) 279 
 280 
3.1.1 Polymer selection for EFV SS formulation 281 
 The miscibility of any drug with a polymer can be outlined via utlizing molecular 282 
orientation based Hoftyzer and Van Krevelen method by means of solubility parameters 283 
calculation [17]. The solubility parameter difference ∆δ between API and polymer provides  284 
possible idea on the miscibility of a particular drug and polymer system [18]. If solubility 285 
parameter difference is less than 7 MPa1/2, itis generally accepted as an indication of miscibility 286 
whereas for a difference of more than 10 MPa1/2 the system is likely to be immiscible. The 287 
underlying concept of the foregoing claim is based on the prediction that the energy of mixing 288 
required for the intermolecular interaction between a drug and polymer will be balanced by the 289 
intramolecular interactions with in the corresponding drug or polymer. EFV is a poorly soluble 290 
drug, having melting point 139 – 140°C with high crystallinity. As reported in literature EFV 291 
shows solubility parameters (δ) value of 24.55 in MPa1/2. Whereas SOL and KVA64 shows 292 
solubility parameters (δ) value of 19.60 MPa1/2 and 19.43 MPa1/2 [13],respectively. This 293 
indicates that the the difference in the solubility parameters (δ) value in EFV/SOL and 294 
EFV/KVA64 systems as 4.95 and 5.12, respectively, which outlines the possibility  of the 295 
formation of miscible systems, hence were proceeded further with the HME processing. 296 
 297 
3.1.2 Box-Behnken Experimental Design 298 
A three factor, three levels BBD was used to study the effect of different ratios of SOL 299 
as well as KVA64, temperature profiles and screw speed on dissolution rate and solubility 300 
enhancement of EFV SS. The experimental results i.e. response data for all experiments are 301 
given in Table 2. The ratio of maximum to minimum amount of each polymer i.e. SOL and 302 
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KVA64 were varied from 30 % to 70% for each. The values of responses for SOL (X1= 303 
Solubility in mg/mL), (X2= Dissolution rate in percentage) varies from lowest to highest values 304 
ranging from 0.987 ± 0.41 to 1.79 ± 0.97 mg/mL and 63.35 ± 4.09 to 100.2 ± 1.97 % whereas 305 
for KVA64 (Y1= Solubility in mg/mL), (Y2= Dissolution rate in percentage) varies from lowest 306 
to highest values ranging from 0.984 ± 0.59 to 1.702 ± 0.72 mg/mL and 48.32 ± 2.39 to 96.32 307 
± 3.67 %.  308 
The ratio of maximum to minimum for both of two responses is 1.83 to 1.42 and 1.92 309 
to 1.53, respectively, concluding there is no requirement of any power transformation. Usually 310 
a value of 10 is a difference that indicates requirement of power transformation. In general 311 
term, a moderately flat line indicates lack of dependence of response on the said factor [25].  312 
 313 
3.1.3 Polynomial equations and response surface analysis 314 
Two-dimensional contour plots and 3D surface plots were prepared for all three 315 
responses of each independent factor viz. variable ratios of SOL and KVA64, variable screw 316 
speed and different temperature and are depicted  in Fig. 2. The independent factor and 317 
response variables were correlated using a polynomial equation with statistical analysis via 318 
Design-Expert® software which confirms that the most significant factors affecting responses 319 
are ratio of SOL and KVA64, variable screw speed and variable temperatures.  320 
 321 
Analysis of variance (ANOVA) was applied to determine effects of variables and their 322 
interactions on responses. Final mathematical model in terms of coded factors as determined 323 
by Design-Expert® software are as follows. 324 
 325 
X1 = +81.69 + 13.10*A1 + 0.72*B+1.80*C – 41.37*ABC+0.65*A+0.028*B+0.051*Eq. (III) 326 
X2= +1.42 + 0.27*A1-0.046*B – 2.75*C + 0.87*ABC + 0.013*A – 1.85*B – 7.85*CEq. (IV) 327 
Y1 = +71.92+18.24*A2 +2.08*B+1.84*C+14.58*ABC+0.91*A+0.083*B+0.052*C    Eq. (V) 328 
Y2 = +1.36 +0.34*A2 + 9.16*B+0.017*C +0.41ABC+0.017*A +3.66*B + 4.74*C     Eq. (VI) 329 
 330 
Where, X1 is solubility and X2 is dissolution rate of SS made from SOL, Y1 is solubility 331 
and Y2 is dissolution rate of SS made from KVA64. A1 is ratio of SOL, B1 is ratio of KVA64, 332 
B is variable screw speed and C is different temperature respectively as independent factors.   333 
The polynomial equations include interaction term and related higher order effects and 334 
coefﬁcients for intercept. A positive sign of coefﬁcient indicate a synergistic effect while 335 
negative term indicates an antagonistic effect upon the respective response. The result from 336 
ANOVA tables for variable responses subsequently confirms fitness of model (i.e. F < 0.05) 337 
(please see the supplementary information). The mathematical relationships, generated using 338 
multiple linear regression analysis, has been used to generate counter plots for independent 339 
factors [26].  The resultant counter plots for all factors and responses are shown in Fig 2. A 340 
relatively flat line in the plots shows lack of dependence of response on the respective 341 
independent factors [25]. 342 
 343 
3.1.4 Effect of independent factors on saturation solubility (X1 and Y1) study 344 
The responses (X1 and Y1) i.e. solubility values of EFV SS, is highlighted as either a  345 
decrease or an increase in solubility of EFV SS. When the  coefficients of factor A (i.e. higher 346 
concentration of SOL) is positive, the highest processing temperature and optimum screw 347 
speed showed maximum solubility of SS. The results of solubility study of EFV SS prepared 348 
by HME showed increase in drug solubility with higher SOL and KVA64 ratio. The solubility 349 
of neat EFV in dissolution medium i.e. 2% SLS solution was found about 0.198 ± 0.81 mg/mL 350 
and in case of SS, the solubility values were found much higher in SS which was increasing 351 
with the increase in the concentration of both SOL and KVA64 processed at maximum barrel 352 
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temperature. The increase in apparent solubility of drug was may be attributed due to formation 353 
of complete amorphous solid solution of EFV [27]. The hydrophilic polymers processed via 354 
HME leads to increase in wettability of drug by decreasing surface tension of SS. As can be 355 
seen inFig. 4, the response surface 3D plot and contour plots shows effect of independent 356 
variables on responses of EFV SS solubility values. The 3D surface plots inferred that when 357 
SOL as well as KVA64 ratio was used in least ratio and at minimum screw speed, it then leads 358 
to lower solubility values. 359 
3.1.5 Effect of independent factors on Dissolution rate (X2 and Y2) studies 360 
In case of response (X2 and Y2), positive coefficients of factor B (i.e. higher 361 
concentration of SOL and KVA64) showed maximum dissolution rate of EFV SS. In contrast, 362 
a negative coefficient of factor A (i.e. higher concentration of both polymers) showed better 363 
dissolution rate. The dissolution profile curves of bulk EFV, optimized batches of EFV ASS10, 364 
BSS9 and Marketed product of EFV are depicted in Fig.3. EFV is a poorly water soluble drug 365 
with a solubility of only 5.2 ± 2.3 µg/mL in water (1). All the dissolution rate values and 366 
dissolution graph in percentages have been shown in supplementary data file of page number 367 
1 and 2.  The glassy solid solution of EFV ASS10 and BSS9 showed highest solubility and 368 
dissolution rate because of drug particles being molecularly dispersed in respective polymer 369 
matrices resulting into formation of SS amorphous system [28]. The dissolution rate and 370 
solubility might be increased due to its increased wettability, greater hydrophilicity, improved 371 
dispersibility and reduction in particle size of the bulk drug. The ASS10 and BSS9 exhibited 372 
similar drug release profiles to that of the marketed tablets with values at about 100, 96 and 373 
97%, respectively. As per the DoE runs, different processing conditions showed different 374 
solubility as well as dissolution rate values attributed to the  effect of independent variables on 375 
the responses.. The differences in dissolution rate among all ASDs seen may be due to 376 
solubilisation nature of polymers, their different ratios, screw speed, barrel temperature as 377 
mentioned in the DoE study (Table 3) which is in resemblance with previously published 378 
literature for other poorly water soluble drugs processed by hot melt extrusion [29, 30]. 379 
3.1.6 DoE post analysis and optimization of EFV SS 380 
The DoE optimization study was carried out to find out level of independent factors A1 381 
(ratio of SOL and A2 (ratio of KVA64) B (screw speed) and C (Barrel temperature) which had 382 
predicted results such as X1 as 1.725 ± 0.1890 mg/mL and X2 as 96.53 ± 1.247% similarly Y1 383 
as 1.725 ± 0.075 mg/mL and Y2 as 94.02 ± 2.278 %. (As shown in Fig.4)  The experimental 384 
values of the results were found as similar as predicted values. The results inferred that the 385 
batch processed at 70% of SOL and KVA64 at 140° C temperature and 75 screw speed had 386 
given the best results. To validate the experimental models, the optimized formulation was 387 
prepared in triplicate by using these values of independent factors and the results are shown in 388 
average of three with standard deviation values. 389 
 The Fig. 4 shows the optimized EFV SS overlay plots by DoE software, stating the 390 
effect of different independent factors on solubility and dissolution rate improvement of EFV 391 
SS prepared using SOL and KVA64 as carriers.  392 
 393 
3.2 DSC analysis 394 
DSC analysis of EFV, SOL, KVA64, ASS10 and BSS9 formulations was carried out 395 
to study the melting temperature and recrystallization behaviour of the crystalline drug. Fig. 3 396 
in supplementary material showed DSC thermograms of all components, which also evaluates 397 
the drug-polymer miscibility and amorphicity of the manufactured extrudates. EFV was 398 
characterized by the Enthalpy (∆H) and a single, sharp melting endothermic peak 102.16 J/g 399 
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and 139.60°C, respectively, whereas SOL and KVA64 did not show any melting endotherm 400 
because of their amorphous nature. SS formulations of EFV showed a complete decrease in 401 
∆H and exhibited no melting endotherms indicating an amorphous existence of the drug. The 402 
DSC findings are in accordance with the PXRD results [31]. Moreover, the drug polymer 403 
miscibility was determined by analyzing the DSC samples at various polymer ratios. The 404 
physical mixtures of EFV and polymers showed an endotherm peak between 137 – 142°C 405 
which is attributed to the presence of the crystalline drug in the blends whereas the SS 406 
formulations showed no thermal peak of EFV indicating complete conversion of EFV into 407 
amorphous form. This result illustrates that crystalline nature of EFV was reduced using HME 408 
technology, by converting it into a stable SS using a polymers like SOL and KVA64.   409 
3.3 XRD analysis 410 
The cryallinity outputs via XRPD analysis of the formulations are summarized in Fig. 411 
4 in supplementary material which shows the diffractograms of pure EFV, SOL, KVA64, 412 
ASS10 and BSS9 formulations.  EFV exhibited characteristic sharp peaks at diffraction angle 413 
(2θ) values of 6.11°,10.43°, 10.98°, 12.27°, 13.25°, 14.20°, 16.92°, 20.14°, 21.25°, and 24.93°, 414 
data resembles with literature [32] which indicates the highly crystalline state of the bulk drug. 415 
Both SOL and KVA64 showed no intensity peaks and thus confirms their amorphous nature. 416 
The melt extrudate SS formulations showed absence of characteristics peak at respective 2θ 417 
angles of pure EFV, which became too broaden and a heap like peaks, which infers a reduction 418 
of the crystallinity of the drug. From XRD results of SS formulations it has been proved that 419 
EFV has been converted to its amorphous form during the high shear HME processing when 420 
combined with amorphous polymeric carriers.. The findings are in good agreement with the 421 
DSC results. The SS formulations which are technically an amorphous system that contain 422 
additional free energy resulting in the solubility enhancement of EFV compared to its bulk 423 
form [33].  424 
3.4 FTIR analysis 425 
The Fourier transform infrared spectroscopy is usually used to study the intermolecular 426 
interactions between components for the formation of stable amorphous solid solution [34, 35]. 427 
The FTIR spectra of EFV, SOL, KVA64, ASS10 and BSS9 are summarized in Fig. 5 in 428 
supplementary material. The FTIR spectra of EFV showed characteristics band  at 3314 cm-1 429 
(for NH stretch vibration), 1742 cm-1 (C=O stretching vibration), 1492 cm-1 (C≡C of benzene 430 
ring stretching vibration), 1240 cm-1 (CN stretch), 1165 cm-1 (CO stretching vibration), 1096, 431 
1057, 1074cm-1 (C-O-C stretch vibration) and 689 and 652 cm-1 (-CF stretch) [36]. In case of 432 
both polymers SOL, KVA64 showed characteristics broad band around 3000-3500 cm−1, C=O 433 
stretch at 1738 cm−1 and 1632 cm−1, and aliphatic C-H stretch at 2932 cm−1 recognized for 434 
presence of maximum number of –OH stretching groups. The hydrogen bond formation 435 
between drugs and polymers has been shown by weak interactions observed at 1033 cm−1 [27, 436 
37]. The carbonyl peaks assigned to free and hydrogen-bonded carboxylic acid C=O appeared 437 
at 1681 cm-1 and 1730 cm-1 in infrared spectra of crystalline EFV, but in case of SS 438 
formulations these peaks were found shifted from original ketone stretch of 1730 cm-1. This 439 
infers that the strength of intermolecular interaction may have exhausted in case of crystal 440 
lattice. Additional hydrogen bond formation was found with hydroxyl group of each polymers 441 
with EFV resulting into a broad peak at 3158 cm−1 [38]. Both polymers showed maximum 442 
number of hydrophilic groups giving maximum hydrophilic surface resulting into diffusion of 443 
dissolution medium and accelerated release of EFV SS. Both EFV SS formulations showed 444 
very similar IR spectra indicated by shifting and broadening of peak of EFV compared to that 445 
of bulk EFV. Ambrogi (2012) et. al. has reported that, formation of hydrogen bond due to weak 446 
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interactions between drug and polymers can be easily wrecked in biological fluids and result 447 
into fast drug release higher solubility for the developed formulations [39].  448 
3.5 AFM analysis 449 
The AFM analysis of EFV SS with respect to their homogeneity was carried out using 450 
AFM analysis. The results are illustrated in Fig. 5a-d. The molecular level roughness data are 451 
depicted in Fig 5 a & c while  3D surface image in Fig. 5 b & d. The AFM images were 452 
determined for illustrating the extrudates morphological surface interactions in detail.  The 453 
phase images illustrated that there is no phase separation between both components indicating 454 
EFV has been adsorbed uniformly by both polymers SOL and KVA64 [22]. Cross sectional 455 
and 3D Topography views of AFM analysis of ASS10 and BSS9 showed that there is high 456 
level of surface interaction between both components each leading to amorphosization of drug 457 
inside polymer system [22, 23]. Molecular solid solution at homogeneous state is directly 458 
related with amorphousness of SS systems. Both extrudates showed complete transparent solid 459 
solution as well as molecular homogeneity. The findings confirm that the AFM images showed 460 
different molecular structure roughness in the cross-sectional extrudates (Fig 5 b & d).  461 
3.6 FTIR chemical imaging analysis 462 
FTIR imaging results have been summarized in Fig. 6. The 3D image and IR reflectance 463 
spectrum of the point of interest of HME SS with 30% w/w loading of EFV specifies the surface 464 
compositional homogeneity. Use of FTIR imaging spectrum provides detailed information of 465 
SS at the molecular level which has been reported in literature (40, 41). FTIR imaging was 466 
constructed basically both on light reflectance and compositional difference at surface of 467 
samples. The homogeneity of EFV in SOL system as illustrated in chemical images, 468 
considerably marked intensity of FTIR reflectance spectrum in region of 1630 to 1740 cm-1 for 469 
amorphous EFV. The band at 1725 cm-1 corresponds to carbonyl group of EFV; H-bonded to 470 
hydroxyl group of  SOL [40, 42]. The 3D graph is illustrated by homogeneity of EFV by orange 471 
- red color and SOL by yellow-green color. From the results of FTIR chemical imaging 472 
analysis, the homogeneity of EFV in SOL matrices was confirmed. The findings are also 473 
complemented by the DSC and XRD  analyses.  474 
3.7 2D COSY NMR analysis: 475 
 The 2D COSY NMR analysis of EFV ASS10, BSS9 has been shown in Fig. 7a and 476 
(Fig.7b in the supplementary file). From the results it can inferred that, cross peaks between 477 
molecular protons within a coupling network were detected at protons range of δ 1.0 – 14.0 of 478 
ASS10 and δ 1.0 – 12.0 in BSS9. The stability of solid-state EFV in the amorphous solid 479 
solution is attributed to the  drug-polymer interactions and its amorphous molecular mobility 480 
is well illustrated by the 2D COSY NMR studies [23]. In case of ASS10, there is proton-proton 481 
coupling observed at various point such as δ 0.8 to 1.0, 1.1 to 1.6, 3.4 to 3.6, 6.1 to 6.6 and 7.45 482 
to 7.6 which states the molecular interaction between the EFV and SOL[43]. The resonance 483 
peaks specific of EFV and both polymers were detected with coupling shifts due to the proton 484 
resonances. Similarly for BSS9 of EFV with KVA64,characteristic cross peaks in the coupling 485 
network at δ 0.5-1.1, 0.5-1.7, 1.1-1.7, 7.1-7.6, 1.15-6.6 and 7.6-7.7 were observed. This proton-486 
proton coupling indicates a high level of molecular interaction between EFV and KVA64. 487 
Moreover, all characteristics drug peak frequencies were observed in SS formulation that 488 
confirms the stable structural and physico-chemical state of EFV in all formulations [13].     489 
 3.8 Drug content by HPLC analysis 490 
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The HPLC drug content analysis of EFV via HPLC and method validation was carried 491 
out as per ICH and FDA guidelines. The linear calibration curve of EFV was plotted with 492 
concentrations  in range of 10-200 µg/mL, with coefficient of regression (R2) value of 0.997. 493 
In HPLC analysis, retention time for EFV was found ~3.38 ± 0.05min. The percent relative 494 
standard deviation (RSD) of the replicate was found less than 2%, demonstrating relative 495 
reproducibility of this method. After extrusion, each SS systems were analyzed for drug content 496 
using HPLC. The results of drug content have been shown in supplementary material.   The SS 497 
samples equivalent to 20 µg/mL were taken from each batch for drug content analysis. All SS 498 
fell within the acceptable range i.e. 95% to 105% of drug content as per US Pharmacopoeia for 499 
EFV tablets. It was found that the drug content of the optimized ASS10 and BSS9 were found 500 
about 98.02 and 100.34%, respectively. The standard deviation value of the formulations was 501 
in range between 0.99 and 2.23 % for all the EFV SS batches. This illustrated that HME 502 
processing conditions revealed excellent content uniformity of EFV in all the formulation 503 
batches.  504 
 505 
Conclusions 506 
 In this context, EFV solid solutions were prepared using SOL and KVA64 as an 507 
amorphous polymeric carriers  using Box Behnken design model. An HME technique was 508 
utilized for the  optimization of EFV SS formulation and process variables. The solid-state 509 
analyses of  EFVconducted by means of DSC. PXRD, FTIR, AFM and FTIR imaging 510 
confirmed the formation of amorphous dispersions of the drug in both polymer matrices . The 511 
crystalline EFV was converted to amorphous state during the extrusion process due to the high 512 
shear force generated during the processing of the formulations. The dissolution rate of EFV 513 
in the developed EFV SS formulations  were significantly higher than that of the marketed 514 
product. About 100% drug was released in less than one hour, whereas marketed formulation 515 
took 60 minutes to show 100% drug release. SOL showed  the highest solubility and dissolution 516 
rate at higher processing temperature and optimum screw speed. Hydrogen bonding between 517 
polymer and EFV played an important role in the increase in the solubilization of EFV and thus 518 
the dissolution enhancement which was then confirmed by both  the FTIR and 2D COSY NMR 519 
analyses. In conclusion, it can be claimed that a QbD approach was adopted to develop and 520 
optimize amorphous solid dispersion of poorly water soluble drug EFV in order to enhance its 521 
dissolution rate and the solubility.   522 
 523 
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